GlassScriptPhysician profile
Hung Nguyen
NPI 1538181763
$4,682.11
in general payments reported to CMS, 2019-2025
32 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $462 · 2021: $995 · 2022: $539 · 2023: $357 · 2024: $1,203 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,006 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,006.00 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $741.50 | 2021-2024 | Vemlidy, Epclusa |
| Astrazeneca Pharmaceuticals LP | $562.44 | 2019-2024 | Farxiga, Lokelma |
| Amarin Pharma, INC. | $480.53 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $438.74 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $374.38 | 2019-2022 | |
| Amgen INC. | $346.66 | 2019-2024 | Repatha |
| Abbvie INC. | $181.62 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.26 | 2020-2023 | Jardiance |
| Genzyme Corporation | $164.67 | 2025 | |
| Novo Nordisk INC | $162.08 | 2021 | |
| Redhill Biopharma INC. | $143.98 | 2024 | Talicia |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $123.49 | 2024 | Voquezna |
| Sunovion Pharmaceuticals INC. | $76.59 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $59.99 | 2023 | Wakix |
| Genentech USA, INC. | $42.75 | 2019-2022 | |
| Pfizer INC. | $41.82 | 2019-2020 | |
| Blue Earth Diagnostics | $32.99 | 2023 | |
| Stryker Corporation | $29.21 | 2025 | Flowtriever |
| Medtronic USA, INC. | $28.06 | 2019 | |
| Allergan, INC. | $26.55 | 2019 | |
| Exact Sciences Corporation | $26.09 | 2025 | The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $24.52 | 2019 | |
| Neotract INC. | $24.01 | 2020 | |
| Abc Home Medical Supply, INC. | $23.70 | 2022 | |
| Avanir Pharmaceuticals, INC. | $21.59 | 2019 | |
| Biogen, INC. | $19.78 | 2020 | |
| Sumitomo Pharma America, INC. | $19.64 | 2025 | Gemtesa |
| Abbott Laboratories | $16.23 | 2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $16.21 | 2019 | |
| Seqirus USA INC | $14.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.